Hims & Hers Health (HIMS) Set to Announce Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) will be announcing its earnings results after the market closes on Monday, August 5th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Hims & Hers Health has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period last year, the firm earned ($0.05) earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Stock Down 5.0 %

NYSE:HIMS opened at $17.58 on Friday. The business’s 50-day simple moving average is $21.37 and its two-hundred day simple moving average is $15.68. The stock has a market cap of $3.78 billion, a PE ratio of -1,758.00 and a beta of 1.08. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $25.74.

Analysts Set New Price Targets

A number of research firms have commented on HIMS. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. TD Cowen raised their price target on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Truist Financial raised their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $16.00 to $20.00 in a report on Wednesday, May 22nd. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus target price of $19.07.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total value of $3,755,093.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total value of $3,755,093.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total value of $30,861.99. Following the completion of the sale, the insider now owns 159,357 shares of the company’s stock, valued at approximately $1,964,871.81. The disclosure for this sale can be found here. Over the last quarter, insiders sold 782,901 shares of company stock worth $16,138,997. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.